Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Califf Closes In On Reprising His FDA Role After Senate Committee Hearing

Executive Summary

After a mostly friendly round of questioning from members of the US Senate committee on health, the confirmation of President Joe Biden’s pick to lead the US FDA seems more likely.

You may also be interested in...



Califf Clears First Senate Hurdle, But Could FDA’s Abortion Pill Access Decision Be A Headache?

Robert Califf’s nomination to be the next US FDA commissioner squeaked out of the Senate health committee, but a significant number of Republicans are against his confirmation over the agency’s recent decisions on abortion drugs.

Califf Sets Departure From US FDA; Ostroff May Become Interim Leader

As FDA Commissioner Robert Califf prepares to step down from his post to make way for a Trump administration replacement, former Acting Commissioner Stephen Ostroff may step into the breach.

News We’re Watching – LivaNova And Medtronic Recalls; Approvals For Abbott And Guardant; Pediatric Device Grants

Recalls on a life-support device used during heart surgery and dialysis tubing were announced this week, as were approvals for a breast cancer companion diagnostic and two cardiac ablation catheters. Additionally, the US FDA has grants available for groups that assist in pediatric device development.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel